Each immune cell group has distinct metabolic requirements, activation pathways, and cytokine reliance. Standard, one-size-fits-all media cannot address these features. When studying diverse cell ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...
The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.
Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results